NASDAQ:CRBP Corbus Pharmaceuticals Q2 2025 Earnings Report $7.54 +0.24 (+3.29%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$7.46 -0.09 (-1.13%) As of 07/8/2025 07:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Corbus Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$1.35Beat/MissN/AOne Year Ago EPSN/ACorbus Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACorbus Pharmaceuticals Announcement DetailsQuarterQ2 2025Date8/5/2025TimeBefore Market OpensConference Call DateTuesday, August 5, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Corbus Pharmaceuticals Earnings HeadlinesCorbus Pharmaceuticals Reports No Neuropsychiatric Events in Phase 1 SAD Study of CRB-913, Advancing to MAD Portion - NasdaqJuly 2, 2025 | nasdaq.comCorbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with PembrolizumabJune 25, 2025 | globenewswire.comWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington. | Altimetry (Ad)Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity SymposiumJune 24, 2025 | globenewswire.comCorbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?June 17, 2025 | seekingalpha.comMizuho Securities Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)May 22, 2025 | theglobeandmail.comSee More Corbus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Corbus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corbus Pharmaceuticals and other key companies, straight to your email. Email Address About Corbus PharmaceuticalsCorbus Pharmaceuticals (NASDAQ:CRBP) (NASDAQ:CRBP) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for patients with rare inflammatory and fibrotic diseases. Headquartered in Norwood, Massachusetts, Corbus applies its expertise in the endocannabinoid system to advance a pipeline of small-molecule drug candidates designed to modulate immune responses and reduce chronic inflammation and fibrosis. The company’s lead investigational therapy, lenabasum, is an oral, selective cannabinoid type 2 (CB2) receptor agonist. Lenabasum is being evaluated in Phase 3 trials for systemic sclerosis and dermatomyositis, two debilitating autoimmune conditions characterized by inflammation and tissue scarring. Corbus is also advancing additional programs—CRB-601 and CRB-602—aimed at addressing unmet medical needs in conditions where dysregulation of innate immune signaling plays a central role. Founded in 2006 under its former name, CB Therapeutics, the company rebranded to Corbus Pharmaceuticals in 2013 following its initial public offering. Over the years, Corbus has established research collaborations with academic institutions and clinical centers across North America and Europe. These partnerships support its rigorous clinical trial programs and facilitate access to patient populations affected by rare diseases. Corbus is led by President and Chief Financial Officer Donald F. McCaffrey, who brings more than two decades of experience in biotechnology finance and operations. The company’s executive team and board of directors comprise seasoned professionals in drug development, regulatory affairs, and commercial strategy, all united by a commitment to bringing new therapies to patients with few treatment options.Written by Jeffrey Neal JohnsonView Corbus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)America Movil (7/15/2025)Wells Fargo & Company (7/15/2025)Citigroup (7/15/2025)Charles Schwab (7/15/2025)Bank of New York Mellon (7/15/2025)Progressive (7/15/2025)JPMorgan Chase & Co. (7/15/2025)UnitedHealth Group (7/15/2025)BlackRock (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
